Current Roles

Employees:
23
Revenue:
$2.9M
About
Nectero Medical is developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms (AAA). The Nectero EAST®, or Endovascular Aneurysm Stabilization Treatment System, delivers a compound with a proprietary molecule known as a Stabilizer Agent to the site of the aneurysm. The Stabilizing Agent: * Inhibits further breakdown of the aneurysm by disrupting the “aortic degradation process”. * Strengthens the vessel wall by cross-linking within the tissue; this wall strengthening lowers the risk of rupture. Our technology allows for earlier intervention in a much safer manner; this can prevent or significantly delay the need for major endovascular (EVAR) or surgical repair. By preventing further degradation of the aneurysm and strengthening the aortic tissue around the aneurysm, many patients can live out their normal life span and never need to face the challenges of EVAR or Surgical repair.
Nectero Medical Address
515 S 48th St
Tempe, AZ
Nectero Medical Email

Past Companies

Nectero MedicalChief Executive Officer
R3 VascularExecutive Chairman
RM Global Partners, LLCManaging Director

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.